GLP-1 Litigation

Ozempic case review.

Sign retainers from claimants who took Ozempic, Wegovy, Mounjaro, or other GLP-1 receptor agonists and developed severe gastroparesis, ileus, or intestinal blockage.

Free, confidential review No fee unless you win Reviewed within 24 hours
Active prospect intake

Ozempic case review

Tell us about your case and a specialist will reach out within one business day.

By submitting this form, you are agreeing by your electronic signature to the Terms and Conditions and Privacy Policy that Claimified and/or its partners may contact you regarding their services by phone or email. You provide your express written consent to receive phone calls (including autodialed and/or pre-recorded/artificial voice calls) and email using automated dialing system at the phone number and email address you provided, even if it is a wireless number, regardless of whether you are on any Federal or state DNC ("Do Not Call") and/or DNE ("Do Not Email") list or registry. In addition, you understand and acknowledge that you are over 18 years of age and your consent is not required as a condition. Your consent can be revoked through any reasonable means. Your telephone company may impose additional charges on subscriber for messages (required for SMS) and there is no obligation to enroll. (Please note the licensed agents are not connected with or endorsed by the U.S. government or any federal program.)

✓

Thank you.

Your case review has been submitted. A specialist will contact you within one business day.

About this campaign

What firms need to know about Ozempic cases.

Ozempic

GLP-1 receptor agonists like Ozempic and Wegovy (semaglutide) and Mounjaro (tirzepatide) have surged in use for diabetes and weight management. Plaintiffs allege manufacturers failed to adequately warn about severe gastrointestinal side effects, including gastroparesis and bowel obstruction.

Claimified screens for documented prescription history, qualifying gastrointestinal diagnosis, and treatment records — including hospitalizations — before any retainer is delivered to a firm.

Qualification criteria

How claimants are pre-screened before they reach your firm.

Every Ozempic lead is vetted on identity, eligibility window, exposure history, and medical fit so your intake team only sees viable cases.

01

Drug and duration

Documented use of Ozempic, Wegovy, Mounjaro, or other GLP-1 for the qualifying duration.

02

Qualifying diagnosis

Gastroparesis, ileus, or intestinal blockage diagnosed and treated, with provider records.

03

Severity

Severity supported by hospitalization, ER visits, or ongoing treatment documentation.

Risk-free delivery

Be early on the GLP-1 mass tort wave.

Pre-qualified, signed Ozempic and GLP-1 claimants — sourced and verified before they ever reach your intake team.

Book a strategy call

More campaigns

Other active mass tort categories.